INTRODUCTION

Gestational diabetes mellitus (GDM) is characterized by impaired glucose tolerance (IGT) with first recognition of onset during pregnancy and is one of the most common complications that can lead to risks for the mother and fetus [1]. The complications related to GDM are macrosomia, shoulder dystocia, still birth, hypertension, and obstetric complications [23]. Abnormal maternal glucose regulation occurs in 3% to 10% of pregnancies, and GDM accounts for 90% of cases of diabetes mellitus (DM) in pregnancy [4]. According to the Korean Health Insurance Database, the prevalence of GDM increased from 5.7% in 2009 to 9.5% in 2011 [5].

The pathogenesis of GDM has not been fully elucidated. The hallmark of GDM is increased insulin resistance. Insulin resistance is a physiologic metabolic change that is regulated during pregnancy to maintain glucose levels for the metabolic demands of the rapidly developing fetus. It is related to anti-insulin hormones secreted by the placenta, including human placental lactogen, prolactin, glucocorticoid, and progesterone [6]. It is well known that the risk of GDM increases among women who are overweight or obese compared with lean or normal-weight women. Therefore, mechanisms linking obesity to insulin resistance, such as type 2 diabetes mellitus (T2DM), are likely to play a role in the development of GDM. In recent years, most studies about this have focused on leptin, resistin, and adiponectin as potential mediators of insulin resistance [7891011121314]. These have been suggested to be implicated in the regulation of placental growth, development, and function and in fetal growth.

However, a few studies have reported on the role of adipokines and insulin resistance in GDM in the Korean population [1516]. Kim [17] reported the similarities and differences from other racial/ethnic groups of GDM in Korean women. GDM is increasing worldwide due in large part to the obesity epidemic. Although the frequency of GDM is relatively low among Korean women, the number of pregnant women with GDM is increasing and GDM remains a concern with advanced maternal age and obesity at pregnancy and excessive weight gain during pregnancy. We evaluated adipokines concentration and insulin resistance according to maternal age or obesity at pregnancy and weight change at diagnosed GDM in the pregnant women with GDM.

METHODS

Participants

In this cross-sectional study, 57 pregnant women with GDM were included between November 2007 and December 2010 at Daegu Catholic University Medical Center. A 50-g 1-hour glucose challenge test was performed at 24 to 28 weeks of gestation. Those patients who had abnormal response (postload plasma glucose ≥140 mg/dL) accordingly underwent a 100-g, 3-hour oral glucose tolerance test (OGTT). Women were diagnosed with GDM if at least two of four diagnostic criteria were met (fasting plasma glucose ≥95 mg/dL, 1-hour plasma glucose ≥180 mg/dL, 2-hour plasma glucose ≥155 mg/dL, or 3-hour plasma glucose ≥140 mg/dL) (Carpenter and Coustan criteria) [18]. Maternal data on age, pre-pregnancy weight and height, and family history of diabetes were acquired from the medical records. Maternal body mass index (BMI) was calculated as weight divided by the square of height (kg/m²). The subjects were classified into three groups according to (1) pre-pregnancy BMI (<25 kg/m² vs. ≥25 kg/m²), (2) maternal age at pregnancy (<35 years old vs. ≥35 years old), and (3) weight change during pregnancy at screening for GDM (weight gain below, within, and in excess of the recommended range). The results were respectively compared in each group. The ideal weight range for pregnancy is based on maternal height and weight before pregnancy. The calculation is based on the guidelines for pregnancy weight gain issued by the Institute of Medicine (IOM) in May 2009 [19], which suggest that recommendations to patients be based on pre-pregnancy BMI. For BMI levels <18.5, 18.5 to 24.9, 25 to 29.9, and >30 kg/m², weight gain ranges are suggested at 28 to 40, 25 to 35, 15 to 25, and 11 to 20 pounds, respectively, and the recommended rates of weight gain are 1 to 1.3, 0.8 to 1, 0.5 to 0.7, and 0.4 to 0.6 pounds/week. The study protocol was approved by the Institutional Review Board of Daegu Catholic University Medical Center (IRB number CR-16-071). Informed consent was exempted by the board due to the retrospective nature of the study.

Biochemical measurements

All laboratory measurements were performed in the morning following an overnight fast (10 to 12 hours) at the time of the 100-g OGTT between 24 and 28 weeks. Glycosylated hemoglobin (HbA1c) levels were measured by high-performance liquid chromatography (Bio-Rad Laboratories, Hercules, CA, USA). Total serum cholesterol, triglyceride, low density lipoprotein cholesterol, and high density lipoprotein cholesterol levels were measured by enzymatic methods using a Hitachi Modular Analytics (Roche, Tokyo, Japan). Serum insulin and c-peptide were measured by electrochemiluminescence immunoassay using Roche Modular (Roche, Basel, Switzerland). For the measurement of adiponectin, a commercially available sandwich immunoassay kit (Human Adiponectin ELISA Kit; Millipore, St. Charles, MO, USA) was used, with intra-assay variability of 7.3% and inter-assay variability of 4.2%. The sensitivity of it was less than 0.5 ng/mL. Leptin was measured by a sandwich immunoassay kit (Human Leptin ELISA Kit; Millipore). The intra-assay coefficient of variation was 4.7% and inter-assay coefficient of variation was 7%. Resistin was quantified using a sandwich enzyme immunoassay kit (Human Resistin Immunoassay; R&D Systems, Minneapolis, MN, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated according to the formula: HOMA-IR=fasting glucose (mmol/L)×fasting insulin (mU/mL)/22.519 [20]. β-Cell function and insulin sensitivity were assessed by HOMA2-%B and HOMA2-%S which were calculated using HOMA2 Computer Model (www.dtu.ox.ac.uk/homa).

Statistical analysis

The summary for basic characteristics was performed using descriptive analysis. The data were represented by mean±standard deviation (SD) for normally distributed values and medians (range) for nonparametric values. The qualitative variables were reported as frequency and percent. Comparisons of clinical parameters according to maternal factor were performed using two sample t-tests with normality or Mann-Whitney U test for nonparametric values. The categorical variables were compared by chi-square test. Differences among groups according to weight change during pregnancy at screening were analyzed by analysis of variance or the Kruskal-Wallis test for nonparametric values. Pearson's correlation coefficient test was applied to assess the correlation between adipokines and clinical parameters, and for non-parametric values, Spearman's correlation was performed. Multivariate analysis was performed using multiple linear regression analysis. All statistical analyses were performed using SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). P<0.05 was considered statistically significant.

RESULTS

The clinical characteristics of the patients with GDM are summarized in Table 1. A total of 57 patents were evaluated in this study. Their mean age was 33.1±3.9 years. Mean pre-pregnancy weight and BMI were 63.5±13.3 kg and 24.7±4.7 kg/m², respectively. Thirty-one patients (approximately 54%) were overweight or obese before pregnancy. Three patients (5.3%) had a history of prior GDM and 22 patients (38.6%) had a family history of DM.

Comparisons of clinical parameters according to pre-pregnancy BMI, maternal age at pregnancy, and weight change during pregnancy at GDM screening are shown in Tables 2, 3, 4.

The clinical parameters such as C-peptide, insulin, HbA1c, triglyceride, and leptin were significantly increased in GDM patients with pre-pregnancy BMI ≥25 kg/m² compared to those with pre-pregnancy BMI <25 kg/m² (Table 2). HOMA-IR (1.3±1.5 vs. 2.1±1.8, P=0.046) and HOMA2-%B (109.5±39.7 vs. 138.7±49.6, P=0.017) were significantly increased in the group with pre-pregnancy BMI ≥25 kg/m², while HOMA2-%S (109.8±43.4 vs. 64.3±24.9, P<0.001) was decreased. There were no significant differences in resistin and adiponectin between these two groups.

In comparisons according to maternal age at pregnancy, HOMA-IR and BMI were higher and adiponectin was lower in the GDM patients with age ≥35 years at pregnancy (Table 3). However, there were no statistically significant differences. In the group aged ≥35 years at pregnancy, a family history of DM was more frequent (56.5% vs. 26.5%, P=0.029).

When classified by weight change during pregnancy at screening, a higher BMI at screening was observed in the group with a weight change in excess of the recommended weight range (25.0±5.1, 27.8±3.3, and 29.9±2.3, P=0.025) (Table 4). Pre-pregnancy BMI was similar among the groups. Although there were no statistically significant differences, leptin was higher in GDM patients who gained above the recommended weight range. Adipokines demonstrated no significant differences among the groups.

The correlations among metabolic parameters are shown in Table 5. Leptin and HOMA-IR were positively correlated with BMI at pregnancy as well as at screening for GDM. HOMA-IR was positively correlated with HOMA2-%B (r=0.413, P=0.001) and negatively correlated with HOMA2-%S (r=−0.581, P<0.001). There were no correlations between insulin resistance and adipokines such as adiponectin, leptin, and resistin.

Multiple linear regression analyses were performed to assess relationships between maternal variables and each of the following variables for which correlation was significant: model I, leptin; model II, HOMA-IR (Table 6). HOMA2-%B was a negative influence of HOMA-IR (β coefficient=−0.007, P<0.001) after adjustment for the other variables.

DISCUSSION

In this study, we examined the features of adipokines and insulin resistance according to the known risk factors of GDM such as pre-pregnancy BMI, maternal age at pregnancy, and weight change during pregnancy at GDM screening in pregnant women with GDM. Leptin, HOMA-IR, and HOMA2-%B at diagnosed GDM were increased in the GDM with obesity (BMI ≥25 kg/m²) before pregnancy. They were positively correlated with BMI both before pregnancy and at screening for GDM. The correlations between adipokines and insulin resistance were not statistically significant. The effect of maternal age at pregnancy and weight change during pregnancy at GDM screening on adipokines and insulin resistance might be less pronounced than the effect of maternal obesity.

Metabolic changes occur during pregnancy. In early gestation, maternal fat is stored and insulin secretion increases, while insulin sensitivity remains unchanged or decreases and insulin resistance and facilitated lipolysis follow in late preg nancy [21]. Pregnancy has been characterized as a diabetogenic state because of the progressive increases in postprandial glucose and the insulin response in the late gestation that decreases up to 50% in insulin-mediate glucose disposal, as well as increases of 200% to 250% in insulin secretion to maintain euglycemia in the mother [212223]. These changes become worse in pregnant women who develop GDM.

Recently, many studies have investigated adkipokines such as adiponectin and leptin, which are secreted only by fat cells, as well as other adipocytokines like resistin and interleukin 6, which can be secreted also by stromal cells in adipose tissue. These are all related to regulation of insulin resistance. In addition, adiponectin, leptin, and resistin are all known to be produced within the intrauterine environment such as the placenta [242526]. Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid oxidation [27]. Circulating adiponectin levels are reduced in patients with GDM as compared to pregnant controls [28]. It leads to aggravate insulin resistance as adiponectin has insulin-sensitizing effects. Leptin is a hormone that helps to regulate energy balance by inhibiting hunger. In obesity, a decreased sensitivity to leptin occurs and results in leptin resistance. Pregnancy is considered a leptin resistant state. Leptin levels reach two- or three-fold higher concentrations compared to the non-pregnant conditions with a peak occurring around 28 weeks of gestation and a decrease to pregravid concentrations observed immediately after delivery [29]. Leptin levels are known to be related to adipose tissue mass and correlated with body fat mass and BMI in both non-pregnant and pregnant women [3031]. Leptin is closely correlated with human choriogonadotrophin throughout pregnancy [32]. Although the results have been controversial, most studies have shown increased leptin in GDM [67913]. Resistin is an adipose-derived hormone similar to a cytokine whose physiologic role has been the subject of much controversy regarding its involvement with obesity and T2DM [33]. Data on circulating resistin in patients with GDM have been inconsistent. Resistin levels in pregnant women are elevated, decreased, or unchanged in the reports [28].

The changes of adipokines and insulin resistance during pregnancy depend on the first, second, or third trimester and result from profound changes in a woman's hormonal status and metabolism [21]. The ability to adjust the nutritional status during this period is very important for the growing fetus in pregnant women. GDM develops when the pancreatic β-cell reserve is insufficient to compensate for decreased insulin sensitivity during pregnancy [2834]. There are some studies of the comparisons of adipokines and insulin resistance between GDM and pregnancy with normal glucose tolerance or IGT in Korea [153536]. However, studies of adipokines and insulin resistance according to maternal factors among GDM patients are few. Oh et al. [15] reported that adiponectin levels were decreased and leptin levels were increased in pregnant women with normal glucose tolerance during 24 to 28 weeks of gestation. Pregnant women with IGT and GDM had significantly elevated resistin compared with those of normal glucose tolerance. In addition, the increased resistin levels were predictors for gestation glucose intolerance.

Risk factors for GDM include advanced gestational age, family history, excessive body weight before pregnancy, and being a nonwhite race such as Black, Hispanic, or Asian. In our study, HOMA-IR, HOMA2-%B, and leptin were significantly increased in GDM patients with obesity (BMI ≥25 kg/m²) before pregnancy (Table 2). HOMA2-%S was decreased. HOMA2-%B increases to compensate for insulin resistance in patients, although pancreatic β-cell reserve is not sufficient. In comparisons of maternal factors at pregnancy, a family history of DM was more frequent for the group aged ≥35 years. Late pregnancy of women with genetic predisposition was high risk for GDM. The IOM and the National Research Council released a report recommending new guidelines for weight gain during pregnancy [19]. It is related with the increase in the number of American women of childbearing age who are overweight and obese, although the relation of weight gain during pregnancy and GDM are controversial. In our study, there were no differences in adiponectin and insulin resistance in the comparisons according to the recommended weight range at GDM screening. At present, the excessive weight gain during pregnancy has been more common. Women who gain excessive weight during pregnancy find it difficult to return to their pre-pregnancy weight, while obese women who gain weight within the guidelines often are able to maintain a lower weight after the pregnancy [37]. The group with excess weight gain showed significantly increased BMI at GDM screening, although pre-pregnancy BMI was similar to the other group.

Leptin and HOMA-IR were positively correlated with BMI both before pregnancy and at screening for GDM in this study. Kautzky-Willer et al. [38] reported a positive correlation between leptin and body weight. Soheilykhah et al. [7] reported that leptin is significantly positively related to insulin and the HOMA index in women with GDM and IGT. Participants in that study were more obese (BMI 26.7±3.7 kg/m²) and had higher leptin levels than those of our study. Adiponectin is negatively correlated to HOMA-IR and there was no correlation found between adiponectin and pre-pregnancy BMI by Vitoratos et al. [8]. In our study, adipokines were not correlated with insulin resistance or insulin sensitivity. Various studies have shown circulating adiponectin levels reduced in patients with GDM compared to normal pregnant women independent of pre-pregnancy BMI and insulin sensitivity [3940]. To clarify the correlation between adiponectin and HOMA-IR in patients with GDM, the change of adipokines caused by insulin resistance related with GDM should be identified.

Our study has some limitations. First, this retrospective analysis was limited by the small sample size at a single center. A large-scale prospective study would overcome these limitations. Second, our study indirectly used of surrogate measures of insulin resistance and β-cell function. Third, when the subjects were classified according to weight change during pregnancy at screening for GDM, we used the recommended rates of weight gain of the IOM guidelines.

In summary, we evaluated the features of adipokines and insulin resistance according to the known maternal risk factors of GDM such as pre-pregnancy BMI, maternal age at pregnancy, and weight change during pregnancy at screening in pregnant women with GDM. HOMA-IR and leptin were increased in GDM patients with obesity at pregnancy. They were positively correlated with BMI before pregnancy and at screening for GDM. The effect of maternal age at pregnancy and weight change during pregnancy at GDM screening on adipokines and insulin resistance might be less pronounced than the effect of maternal obesity.

Although most women diagnosed with GDM return to normal glucose tolerance soon after delivery, some have IGT or T2DM. Leptin and HOMA-IR were increased in GDM patients with obesity before pregnancy and positively correlated with BMI both before pregnancy and at screening for GDM. It might be necessary to stratify GDM patients according to clinical characteristics and modify the strategy for management of GDM.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997. Diabetes Care 1998;21(Suppl 2):B1-B167.
• 2. Khatun N, Latif SA, Uddin MM. Pregnancy associated complications of mothers with gestational diabetes mellitus. Mymensingh Med J 2005;14:196-198. PubMed
• 3. Jawerbaum A, Gonzalez E. Diabetic pregnancies: the challenge of developing in a pro-inflammatory environment. Curr Med Chem 2006;13:2127-2138. ArticlePubMed
• 4. Moore TR, Griffing GT, Khardori R, Talavera F, Warshak C, Zurawin RK. Diabetes mellitus and pregnancy updated 2017 Fab 14. Available from: http://emedicine.medscape.com/article/127547-overview.
• 5. Koo BK, Lee JH, Kim J, Jang EJ, Lee CH. Prevalence of gestational diabetes mellitus in Korea: a National Health Insurance Database Study. PLoS One 2016;11:e0153107. ArticlePubMedPMC
• 6. Gao XL, Yang HX, Zhao Y. Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. Chin Med J (Engl) 2008;121:701-705. PubMed
• 7. Soheilykhah S, Mojibian M, Rahimi-Saghand S, Rashidi M, Hadinedoushan H. Maternal serum leptin concentration in gestational diabetes. Taiwan J Obstet Gynecol 2011;50:149-153. ArticlePubMed
• 8. Vitoratos N, Deliveliotou A, Vlahos NF, Mastorakos G, Papadias K, Botsis D, Creatsas GK. Serum adiponectin during pregnancy and postpartum in women with gestational diabetes and normal controls. Gynecol Endocrinol 2008;24:614-619. ArticlePubMed
• 9. Mokhtari M, Hashemi M, Yaghmaei M, Naderi M, Shikhzadeh A, Ghavami S. Evaluation of the serum leptin in normal pregnancy and gestational diabetes mellitus in Zahedan, southeast Iran. Arch Gynecol Obstet 2011;284:539-542. ArticlePubMedPDF
• 10. Xiao L, Zhao JP, Nuyt AM, Fraser WD, Luo ZC. Female fetus is associated with greater maternal insulin resistance in pregnancy. Diabet Med 2014;31:1696-1701. ArticlePubMedPDF
• 11. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia. Diabetologia 2010;53:268-276. ArticlePubMedPDF
• 12. Pfau D, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lossner U, Bluher M, Stumvoll M, Fasshauer M. Circulating levels of the adipokine chemerin in gestational diabetes mellitus. Horm Res Paediatr 2010;74:56-61. ArticlePubMedPDF
• 13. Horosz E, Bomba-Opon DA, Szymanska M, Wielgos M. Third trimester plasma adiponectin and leptin in gestational diabetes and normal pregnancies. Diabetes Res Clin Pract 2011;93:350-356. ArticlePubMed
• 14. Soheilykhah S, Mohammadi M, Mojibian M, Rahimi-Saghand S, Rashidi M, Hadinedoushan H, Afkhami-Ardekani M. Maternal serum adiponectin concentration in gestational diabetes. Gynecol Endocrinol 2009;25:593-596. ArticlePubMed
• 15. Oh ES, Han JH, Han SM, Im JA, Rhee EJ, Park CY, Oh KW, Lee WY. Adipokine concentrations in pregnant Korean women with normal glucose tolerance and gestational diabetes mellitus. Korean Diabetes J 2009;33:279-288.Article
• 16. Cho AR, Kim YJ, Chun SH, Cho SJ, Park EA, Park MH. Concentration of cord serum adiponectin in normal and gestational diabetic pregnancies. Korean J Obstet Gynecol 2011;54:485-491.Article
• 17. Kim C. Gestational diabetes mellitus in Korean women: similarities and differences from other racial/ethnic groups. Diabetes Metab J 2014;38:1-12. ArticlePubMedPMC
• 18. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982;144:768-773. ArticlePubMed
• 19. Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. Rasmussen KM, Yaktine ALWeight gain during pregnancy: reexamining the guideline. Washington (DC): National Academies Press (US); 2009.
• 20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. ArticlePubMedPDF
• 21. Zavalza-Gomez AB, Anaya-Prado R, Rincon-Sanchez AR, Mora-Martinez JM. Adipokines and insulin resistance during pregnancy. Diabetes Res Clin Pract 2008;80:8-15. ArticlePubMed
• 22. Ramos MP, Crespo-Solans MD, del Campo S, Cacho J, Herrera E. Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness. Am J Physiol Endocrinol Metab 2003;285:E318-E328. ArticlePubMed
• 23. Malek A, Sager R, Schneider H. Effect of hypoxia, oxidative stress and lipopolysaccharides on the release of prostaglandins and cytokines from human term placental explants. Placenta 2001;22(Suppl A):S45-S50. ArticlePubMed
• 24. Arner P. Insulin resistance in type 2 diabetes: role of the adipokines. Curr Mol Med 2005;5:333-339. ArticlePubMed
• 25. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-1159. ArticlePubMedPDF
• 26. Bowen JM, Chamley L, Mitchell MD, Keelan JA. Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. Placenta 2002;23:239-256. ArticlePubMed
• 27. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300. ArticlePubMed
• 28. Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol (Oxf) 2012;76:2-11. ArticlePubMed
• 29. Schubring C, Englaro P, Siebler T, Blum WF, Demirakca T, Kratzsch J, Kiess W. Longitudinal analysis of maternal serum leptin levels during pregnancy, at birth and up to six weeks after birth: relation to body mass index, skinfolds, sex steroids and umbilical cord blood leptin levels. Horm Res 1998;50:276-283. ArticlePubMedPDF
• 30. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295. ArticlePubMed
• 31. Misra VK, Trudeau S. The influence of overweight and obesity on longitudinal trends in maternal serum leptin levels during pregnancy. Obesity (Silver Spring) 2011;19:416-421. ArticlePubMedPDF
• 32. Hardie L, Trayhurn P, Abramovich D, Fowler P. Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy. Clin Endocrinol (Oxf) 1997;47:101-106. ArticlePubMedPDF
• 33. Lazar MA. Resistin- and obesity-associated metabolic diseases. Horm Metab Res 2007;39:710-716. ArticlePubMed
• 34. Al-Badri MR, Zantout MS, Azar ST. The role of adipokines in gestational diabetes mellitus. Ther Adv Endocrinol Metab 2015;6:103-108. ArticlePubMedPMCPDF
• 35. Park S, Kim MY, Baik SH, Woo JT, Kwon YJ, Daily JW, Park YM, Yang JH, Kim SH. Gestational diabetes is associated with high energy and saturated fat intakes and with low plasma visfatin and adiponectin levels independent of prepregnancy BMI. Eur J Clin Nutr 2013;67:196-201. ArticlePubMedPDF
• 36. Jo YK, Im JA. Adiponectin level in non-pregnant women, pregnant women without diabetes and pregnant women with diabetes. J Exp Biomed Sci 2008;14:233-238.
• 37. Bloomgarden ZT. Gestational diabetes mellitus and obesity. Diabetes Care 2010;33:e60-e65. ArticlePubMedPMCPDF
• 38. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, Prager R, Waldhausl W. Increased plasma leptin in gestational diabetes. Diabetologia 2001;44:164-172. ArticlePubMedPDF
• 39. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care 2004;27:799-800. PubMed
• 40. Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, Cetin I, Cortelazzi R, Beck-Peccoz P, Spada A. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf) 2007;66:447-453. ArticlePubMed

Table 1

Basic characteristics of the subjects (n=57)

Variable	Value
Age at screening, yr	33.1±3.9
Pre-pregnancy weight, kg	63.5±13.3
Pre-pregnancy BMI, kg/m2	24.7±4.7
Weight at screening for GDM, kg	70.1±12.0
BMI at screening for GDM, kg/m2	27.3.±4.2
Weight changea, kg	6.6±5.1
Fasting glucose, mg/dL	89.1±12.6
C-peptide, ng/mL	1.9±0.9
Insulin, µIU/mL	7.6±6.7
HbA1c, %	5.5±0.4
Cholesterol, mg/dL	213.2±40.7
Triglyceride, mg/dL	221.7±105.4
HDL-C, mg/dL	66.5±14.3
LDL-C, mg/dL	102.3±40.4
HOMA-IR	1.7±1.4
HOMA2-%B	122.8±46.4
HOMA2-%S	89.6±42.2
Leptin, ng/mL	16.4±9.5
Resistin, ng/mL	36.3±25.2
Adiponectin, ng/mL	5,439.1±2,667.8
GDM Hx	3 (5.3)
Family Hx	22 (38.6)

Values are presented as mean±standard deviation or number (%).

BMI, body mass index; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA2-%B, homeostasis model assessment of insulin resistance 2-%B; HOMA2-%S, homeostasis model assessment of insulin resistance 2-%S; GDM, gestational diabetes mellitus; Hx, history.

^aDuring pregnancy at screening for GDM.

Table 2

Comparisons of clinical parameters according to pre-pregnancy BMI

Variable	<25 kg/m2 (n=31)	≥25 kg/m2 (n=26)	P value
Age at screening, yr	33.0±3.7	33.2±4.2	0.884
Pre-pregnancy BMI	21.2±2.1	28.9±3.1	<0.001a
BMI at screening for GDM	24.3±2.9	30.9±2.4	<0.001a
Weight changeb	7.6±4.8	5.4±5.3	0.098
Fasting glucose	86.6±10.8	92.1±14.2	0.100
C-peptide	1.5±0.7	2.4±0.9	<0.001a
Insulin	3.9 (2.0–41.0)	7.8 (2.8–22.1)	0.012a
HbA1c	5.4±0.4	5.7±0.4	0.007a
Cholesterol	210.8±37.7	216.0±44.5	0.640
Triglyceride	185.0±87.5	265.5±109.7	0.003a
HDL-C	69.8±15.4	62.6±11.9	0.055
LDL-C	104.0±33.3	100.3±48.1	0.732
HOMA-IR	1.3±1.5	2.1±1.8	0.046a
HOMA2-%B	109.5±39.7	138.7±49.6	0.017a
HOMA2-%S	109.8±43.4	64.5±24.9	<0.001a
Leptin	13.9±7.0	19.3±11.3	0.039a
Resistin	37.8±28.7	34.5±20.6	0.615
Adiponectin	4,833.0 (2,181.0–11,726.5)	4,412.5 (2,173.0–14,781.0)	0.943
GDM Hx	2 (6.5)	1 (3.8)	0.661
Family Hx	11 (35.5)	11 (42.3)	0.598

Values are presented as mean±standard deviation, median (range), or number (%).

BMI, body mass index; GDM, gestational diabetes mellitus; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA2-%B, homeostasis model assessment of insulin resistance 2-%B; HOMA2-%S, homeostasis model assessment of insulin resistance 2-%S; Hx, history.

^aP<0.05, ^bDuring pregnancy at screening for GDM.

Table 3

Comparisons of clinical parameters according to maternal age at pregnancy

Variable	<35 Years (n=34)	≥35 Years (n=23)	P value
Age at screening, yr	30.3±2.1	37.2±1.5	<0.001a
Pre-pregnancy BMI	24.4±4.7	25.1±4.6	0.598
BMI at screening for GDM	26.8±4.6	28.0±3.6	0.290
Weight changeb	6.1±5.1	7.4±11.9	0.338
Fasting glucose	89.6±12.5	88.4±13.1	0.713
C-peptide	2.0±1.0	1.8±0.8	0.406
Insulin	5.7 (2.0–20.1)	5.3 (2.0–41.0)	0.481
HbA1c	5.6±0.5	5.5±0.4	0.385
Cholesterol	210.5±43.4	217.1±36.9	0.555
Triglyceride	208.9±98.3	240.7±114.8	0.269
HDL-C	69.9±14.7	67.4±13.8	0.690
LDL-C	102.9±42.0	101.5±38.9	0.902
HOMA-IR	1.6±1.2	1.8±1.7	0.597
HOMA2-%B	124.0±50.5	121.0±40.8	0.815
HOMA2-%S	87.5±44.0	92.7±40.0	0.651
Leptin	17.0±10.2	15.5±8.5	0.583
Resistin	26.8 (2.03–85.8)	25.7 (12.49–85.8)	0.953
Adiponectin	4,868.8 (2,173.0–14,781.0)	4,433.5 (2,242.0–12,969.0)	0.205
GDM Hx	2 (5.9)	1 (4.3)	0.645
Family Hx	9 (26.5)	13 (56.5)	0.029a

Values are presented as mean±standard deviation, median (range), or number (%).

BMI, body mass index; GDM, gestational diabetes mellitus; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA2-%B, homeostasis model assessment of insulin resistance 2-%B; HOMA2-%S, homeostasis model assessment of insulin resistance 2-%S; Hx, history.

^aP<0.05, ^bDuring pregnancy at screening for GDM.

Table 4

Comparisons of clinical parameters according to the weight change during pregnancy at screening for GDM

Variable	<Δa kg (n=28)	Δa kg (n=20)	>Δa kg (n=9)	P value
Age at screening, yr	32.4±3.7	34.2±3.9	32.8±4.5	0.270
Pre-pregnancy BMI	25.0±5.1	24.3±3.3	24.8±2.9	0.948b
BMI at screening for GDM	25.0±5.1	27.8±2.4	29.9±2.3	0.025b,c
Weight changed	7.6±4.8	5.4±5.3	6.1±5.1	<0.001c
Fasting glucose	90.2±12.6	88.5±12.7	87.1±13.7	0.796
C-peptide	1.8±0.8	2.1±1.1	1.8±0.8	0.743
Insulin	6.4±4.6	9.9±9.2	6.1±4.2	0.164
HbA1c	5.8±0.4	5.5±0.4	5.5±0.6	0.895
Cholesterol	206.6±42.4	219.2±37.2	220.3±43.7	0.714
Triglyceride	212.1±92.0	248.6±118.4	192.0±113.1	0.332
HDL-C	66.7±13.0	67.3±18.1	64.2±8.0	0.879b
LDL-C	97.5±39.3	102.2±38.1	117.7±49.0	0.841
HOMA-IR	1.4±1.1	2.2±1.8	1.3±0.9	0.160
HOMA2-%B	115.6±44.0	131.4±52.0	125.8±46.4	0.506
HOMA2-%S	93.7±43.7	81.3±35.4	95.1±52.4	0.559
Leptin	16.1±9.4	16.5±9.7	17.0±10.4	0.973
Resistin	37.9±27.1	32.9±22.5	38.9±26.5	0.755
Adiponectin	5,693.2±2,436.4	5,006.3±2,837.4	5,610.6±3,152.6	0.672
GDM Hx	2 (7.1)	1 (5.0)	0	0.716
Family Hx	8 (28.6)	9 (45.0)	5 (55.6)	0.290

Values are presented as mean±standard deviation or number (%).

GDM, gestational diabetes mellitus; BMI, body mass index; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA2-%B, homeostasis model assessment of insulin resistance 2-%B; HOMA2-%S, homeostasis model assessment of insulin resistance 2-%S; Hx, history.

^aRecommended range, ^bKruskal-Wallis test, ^cP<0.05, ^dDuring pregnancy at screening for GDM.

Table 5

Correlation between adipokines and clinical parameters

Variable	Adiponectina		Resistin		Leptin		HOMA-IR
	r	P value	r	P value	r	P value	r	P value
Age, yr	−0.172	0.200	−0.036	0.789	−0.132	0.327	−0.034	0.802
Pre-pregnancy BMI	−0.074	0.585	−0.048	0.725	0.422	0.001b	0.309	0.019b
BMI at screening for GDM	−0.071	0.599	−0.075	0.581	0.407	0.002b	0.339	0.010b
Weight changec	−0.064	0.635	0.023	0.866	−0.111	0.413	−0.012	0.932
Fasting glucose	0.035	0.798	0.039	0.774	−0.041	0.762	0.193	0.150
C-peptide	0.028	0.835	0.010	0.944	0.224	0.093	0.629	<0.001b
Insulin	−0.106	0.433	−0.109	0.420	0.170	0.205	0.981	<0.001b
HOMA-IR	−0.110	0.416	−0.099	0.465	0.171	0.203	-	-
HOMA2-%B	0.030	0.824	−0.059	0.664	0.227	0.089	0.413	0.001b
HOMA2-%S	−0.148	0.272	0.103	0.446	−0.211	0.116	−0.581	<0.001b
Leptin	−0.007	0.956	−0.125	0.353	-	-	0.171	0.203
Resistin	−0.208	0.121	-	-	−0.125	0.353	−0.099	0.465
Adiponectin	-	-	−0.208	0.121	−0.007	0.956	−0.110	0.416

HOMA-IR, homeostasis model assessment of insulin resistance; BMI, body mass index; GDM, gestational diabetes mellitus; HOMA2-%B, homeostasis model assessment of insulin resistance 2-%B; HOMA2-%S, homeostasis model assessment of insulin resistance 2-%S.

^aSpearman's correlation, ^bP<0.05, ^cDuring pregnancy at screening for GDM.

Table 6

Multiple linear regression analysis

Variable	β Coefficient	Standard error	t	P value
Model I (Leptin)
Pre-pregnancy BMI	0.599	0.589	1.017	0.314
BMI at screening for GDM	0.320	0.650	0.492	0.624
Model II (HOMA-IR)
Pre-pregnancy BMI	−0.006	0.008	−0.683	0.498
BMI at screening for GDM	0.013	0.009	1.534	0.131
C-peptide	0.386	0.039	9.886	<0.001a
Insulin	0.199	0.003	67.334	<0.001a
HOMA2-%B	−0.007	0.001	−13.032	<0.001a
HOMA2-%S	0.000	0.000	0.715	0.478

BMI, body mass index; GDM, gestational diabetes mellitus; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA2-%B, homeostasis model assessment of insulin resistance 2-%B; HOMA2-%S, homeostasis model assessment of insulin resistance 2-%S.

^aP<0.05.

Figure & Data

References

Citations

Citations to this article as recorded by  

• L-ergothioneine reduces mitochondrial-driven NLRP3 activation in gestational diabetes mellitus
  Colm J. McElwain, Andrea Musumeci, Samprikta Manna, Fergus P. McCarthy, Cathal M. McCarthy
  Journal of Reproductive Immunology.2024; 161: 104171.     CrossRef
• The therapeutic effects of attending a one-day outpatient service on patients with gestational diabetes and different pre-pregnancy body mass indices
  Yan-Min Cao, Min Ma, Wei Wang, Na-Na Cai
  Frontiers in Public Health.2023;[Epub]     CrossRef
• Insulin Resistance in Gestational Diabetes Mellitus and Its Association With Anthropometric Fetal Indices
  Tuan Dinh Le, Tien Minh Bui, Trinh Hien Vu, Nga Phi Thi Nguyen, Hoa Thanh Thi Tran, Son Tien Nguyen, Lan Ho Thi Nguyen, Manh Van Ngo, Hoang Huy Duong, Binh Thanh Vu, Hoa Trung Dinh, Binh Nhu Do, Duc-Cuong Le, Hien Thi Nguyen, Kien Trung Nguyen
  Clinical Medicine Insights: Endocrinology and Diabetes.2022; 15: 117955142210984.     CrossRef
• New Insights into Adipokines in Gestational Diabetes Mellitus
  Jorge Valencia-Ortega, Rebeca González-Reynoso, Edgar G. Ramos-Martínez, Aldo Ferreira-Hermosillo, María I. Peña-Cano, Enrique Morales-Ávila, Renata Saucedo
  International Journal of Molecular Sciences.2022; 23(11): 6279.     CrossRef
• The combination from ethanol extract of moringa leaves (Moringa oleifera L.) and ethanol extract of papaya leaves (Carica papaya L.) slows the tumor growth in sprague dawley rats induced 7,12-dimethylbenz(a)anthracene
  Mutmainah Arif, Ika Yustisia, Padlianah
  Medicina Clínica Práctica.2020; 3: 100100.     CrossRef
• Insulin resistance (IR) in pregnant women at the Mother and Child Hospital Khadijah, Makassar, Indonesia
  Hasbobi Tabrang, Elizabet C. Jusuf, Himawan Sanusi
  Enfermería Clínica.2020; 30: 84.     CrossRef
• Vitamin D Deficiency at Mid-Pregnancy Is Associated with a Higher Risk of Postpartum Glucose Intolerance in Women with Gestational Diabetes Mellitus
  Kyung-Soo Kim, Seok Won Park, Yong-Wook Cho, Soo-Kyung Kim
  Endocrinology and Metabolism.2020; 35(1): 97.     CrossRef
• Involvement of the Endocrine-Disrupting Chemical Bisphenol A (BPA) in Human Placentation
  Sophie-Christine de Aguiar Greca, Ioannis Kyrou, Ryan Pink, Harpal Randeva, Dimitris Grammatopoulos, Elisabete Silva, Emmanouil Karteris
  Journal of Clinical Medicine.2020; 9(2): 405.     CrossRef
• Joint Associations of Maternal Gestational Diabetes and Hypertensive Disorders of Pregnancy With Overweight in Offspring
  Yuying Gu, Jun Lu, Weiqin Li, Huikun Liu, Leishen Wang, Junhong Leng, Wei Li, Shuang Zhang, Shuting Wang, Jaakko Tuomilehto, Zhijie Yu, Xilin Yang, Andrea A. Baccarelli, Lifang Hou, Gang Hu
  Frontiers in Endocrinology.2019;[Epub]     CrossRef
• Reduced Serum Adiponectin Level and Risk of Poststroke Depression in Patients with Ischemic Stroke
  Junhua Yang, Guanghui Du, Jinyu Wang, Jia Chen, Chenghui Yang, Jia Li, Yun Zhang
  Journal of Stroke and Cerebrovascular Diseases.2019; 28(2): 305.     CrossRef
• Letter: Adipokines and Insulin Resistance According to Characteristics of Pregnant Women with Gestational Diabetes Mellitus (Diabetes Metab J 2017;41:457-65)
  Ohk-Hyun Ryu
  Diabetes & Metabolism Journal.2018; 42(1): 87.     CrossRef
• The importance of treating mild hyperglycemia in pregnant women with diabetes
  Kyung-Soo Kim
  The Korean Journal of Internal Medicine.2018; 33(6): 1079.     CrossRef
• Response: Adipokines and Insulin Resistance According to Characteristics of Pregnant Women with Gestational Diabetes Mellitus (Diabetes Metab J 2017;41:457-65)
  Eon Ju Jeon, Ji Hyun Lee
  Diabetes & Metabolism Journal.2018; 42(1): 90.     CrossRef

About this article

Jeon EJ, Hong SY, Lee JH. Adipokines and Insulin Resistance According to Characteristics of Pregnant Women with Gestational Diabetes Mellitus. Diabetes Metab J. 2017;41(6):457-465.

Received: Feb 04, 2017; Accepted: Sep 08, 2017

DOI: https://doi.org/10.4093/dmj.2017.41.6.457.

Download citation ↓